Kornimate/medical-research-clean huggingface dataset:
citrate anticoagulation vs. heparin-coated dialyzers

Conditions: Dialysis

Summary: hemodialysis causes contact activation of the coagulation pathway (1). for this reason, unfractionated or low molecular weight heparins are administered in daily practice to prevent thrombosis of the dialyzer and blood circuit, but the dose commonly used causes systemic anticoagulation. this can cause serious complications in patients with high risk of bleeding. regional and low-dose heparinization, use of prostacycline, regional citrate anticoagulation (rca), and high-flow-rate hemodialysis without anticoagulation have been shown to reduce bleeding complications. each of these methods, however, is characterized by its own technical difficulties, limitations, or complications. the present study aimed to compare the efficacy and safety of heparin-coated polyacrylonitrile membranes (an69st) and regional citrate anticoagulation in hemodialysis patients at risk of bleeding

1. open label single centre prospective randomized trial including 33 patients aged over 18 years with chronic kidney disease stage 5 requiring intermittent hemodialysis at the university hospital leuven and at risk of bleeding. exclusion criteria were: any haemostatic disorder favouring either bleeding or clotting, anti-vitamin k or heparin treatment, heparin induced thrombocytopenia and haemodynamic instability. written informed consent before enrolment. 2. random allocation (by sealed enveloppe) to rca with a calcium free dialysate (rca-ca0), rca with a calcium containing dialysate (rca-ca1,5) or to anticoagulant-free hemodiaysis with a heparin-coated polyacrylonitrile membrane (nephral 300st®). 3. at the end of each dialysis session, arterial and venous drip chambers and the filter will be inspected for visible signs of coagulation. corresponding to the standard care at our dialysis unit, a semi-quantitative score with a range from 0 (no signs of clotting) to 4 (complete occlusion) will be used for evaluation of the dialyzer. by definition, the drip chamber will be considered clotted when a thrombus was visible after the rinse back procedure. a fibrin ring against the wall of the drip chamber will be considered normal. 4. blood samples for assessment of prothrombin fragment f1+2 and d-dimers will be collected from the inlet blood catheter prior to hemodialysis initiation and during hemodialysis at t15, t120 and t238.

Eligibility criteria:
inclusion criteria: * aged over 18 years * chronic kidney disease stage 5 requiring intermittent hemodialysis * at risk of bleeding * written informed consent exclusion criteria: * any haemostatic disorder favouring either bleeding or clotting * anti-vitamin k or heparin treatment * heparin induced thrombocytopenia * haemodynamic instability

Keywords: citrate anticoagulation heparin-coated membrane
the role of traditional chinese medicine in the treatment of chronic childhood immune thrombocytopenia (itp)

Conditions: Childhood Chronic Immune Thrombocytopenia

Summary: immune thrombocytopenia (itp) is an autoimmune disorder manifested as isolated low platelet count which results in a tendency for bleeding. around 10% of childhood itp does not reach resolution within 1 year thus becoming chronic itp. therapeutic modalities at present are aimed to achieve symptomatic relief, do not change the natural course of the disorder and are associated with potential side effects and increase cost. thus, identifying a new therapy that would decrease the bleeding symptoms, without causing significant adverse effects, could be very beneficial. preliminary reports demonstrate a beneficial role for traditional chinese medicine (tcm) in the treatment of itp. working hypothesis and aims: the use of tcm will improve the status of children with chronic itp and thus will reduce the need to use conventional medications. the investigators aim to study whether in children with chronic itp, supplementation with tcm, improves the bleeding symptoms and itp-related quality of life (qol) compared to the period prior to the intervention? methods: the study includes three periods: 1st observation period (1 month), tmc period (3 months) and 2nd observation period (2 months). during all study periods the following data will be collected: bleeding symptoms, bleeding score, platelet count, need for conventional therapy, side effects of therapy and itp-related qol.


Eligibility criteria:
inclusion criteria: 1. children (\ 1 year after a first diagnosis and baseline platelet count \< 30,000. the diagnosis of itp will be the responsibility of the pediatric hematology specialist in each participating center. - exclusion criteria: 1. children with thrombocytopenia due to other causes. 2. refusal of child or guardian to participate. -
epidemiology and cost-effectiveness of out-of-hospital cardiac arrest in finland

Conditions: Cardiac Arrest

Summary: observational study of all out-of-hospital cardiac arrest during 6 months in regional areas of helsinki university hospital and kuopio university hospital from activation of ems system until follow up to 6 months of survival.simultaneous observation of out-of-hospital cardiac arrest primary survivors admitted to all finnish icus.


Eligibility criteria:
inclusion criteria: * out-of-hospital cardiac arrest patients exclusion criteria: * none

Keywords: cardiac arrest intensive care unit emergency medical service
effect of exercises on pain, functional disability and lumbar stability in patients with low back pain

Conditions: Exercise

Summary: the purposes of this study are to compare the effects of core stabilization exercises on pain intensity, functional disability and lumbar stability between using and not using the swiss ball in patients with non-specific chronic low back pain.

for patient registries: the participant was screened for inclusion criteria and was asked to sign the informed consent prior to participate. a randomized control trial was performed with participants randomly divided into one of the two treatment groups: core stabilization exercise with ball and core stabilization exercise without ball by using sealed envelopes.

Eligibility criteria:
inclusion criteria: 1. male and female with low back pain (lbp) \> 3 months 2. body mass index (bmi) = 18-25 kg/m2 3. non-specific lbp (pain at the lower lumbar between costal margin but not below gluteal fold) 4. willing and able to perform exercise programs 5. no cognitive impairment 6. age at least 19 years exclusion criteria: 1. having experiences in the core stabilization exercise and swiss ball exercises 2. past history of back and abdomen surgery 3. recent fractures of spine, hip or lower limb 4. current use of steroids or any other drugs for resolving back pain 5. red flags (fractures, cancer, infection, cauda equine syndrome) 6. pregnancy 7. neuromuscular or respiratory disorders 8. rheumatologic disorders 9. hip and knee stiffness 10. pain intensity \> 60 of 100 mm assessed by the vas

Keywords: exercise
tobacco cessation care for cancer patients by automated interactive outreach

Conditions: Cancer; Tobacco Dependence; Tobacco Use Cessation

Summary: this is a multi-arm, randomized controlled, pilot study which will recruit cancer patients who have been seen by a ucsf cancer center-affiliated clinical department to evaluate the efficacy of "careconnect". this is the first study to assess the efficacy careconnect, a combination of the ask-advise-connect (aac) with an interactive voice response (ivr) delivering cancer-targeted educational messages to support referral to smoking cessation resources for patients with cancer.

primary objective: i. to evaluate careconnect's efficacy on referring patients to tobacco cessation resources. secondary objective: i. to evaluate patients' acceptance of referrals. ii. to evaluate the acceptability of careconnect. exploratory objectives: i. in-depth semi-structured qualitative interviews of 20 selectively chosen participants who completed the 3-month follow-up survey or finished the automated careconnect or auto-reach call but may have refused to complete the 3-month follow-up survey (10 from each group). ii. smoking cessation with verification. outline: eligible participants, identified through the cancer center tobacco registry will be randomized to either the intervention or control arm on a 1:1 ratio. participants who complete the first call of careconnect or autoreach will be considered enrolled. participants will complete a baseline assessment, a 3-month assessment, and have option to provide a saliva sample. for those who are selected to participate in an in-depth interview, this will take place within 1 month after the 3-month assessment. data from the participants medical record may be accessed at 6 months post follow-up.

Eligibility criteria:
inclusion criteria: 1. age 18 years and older. 2. able to understand study procedures and to comply with them for the entire length of the study. 3. ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it. 4. english, spanish, cantonese, or mandarin speaking. 5. self-reported current use of tobacco, including e-cigarette on ehr. 6. has a diagnosis of cancer. 7. has been seen by a prescribing provider within a ucsf cancer center-affiliated clinical department within the past 3 months. exclusion criteria: 1. contraindication to any study-related procedure or assessment. 2. no valid contact telephone number. 3. currently hospitalized or having been discharged from inpatient setting within the past month (according to ehr).

Keywords: interactive intervention
the effect of pacap27 on the extra- and intracerebral arteries assessed by magnetic resonance angiography (mra) on healthy volunteers

Conditions: Headache, Migraine

Summary: studying pituitary adenylate cyclase-activating peptide 27 (pacap27) effects on extra- and intracerebral arteries assessed by mra on healthy volunteers.

pacap neuropeptide, which belongs to the vasoactive intestinal polypeptide (vip)/glucagon/secretin family. pacap exists in two forms: studying pituitary adenylate cyclase-activating peptide 38 (pacap38), which consists of 38 amino acids and pacap27 which contains 27 amino acids at its n-terminus. pacap38 is implicated in migraine pathophysiology however pacap27 is not studied well. therefore, the investigators will study pacap27's effect on extra- and intracerebral arteries assessed by mra on healthy volunteers.

Eligibility criteria:
inclusion criteria: * healthy volunteers * aged 18-50 * 50-100 kg exclusion criteria: * tension type headache more than 5 dag /month * other primary headaches * daily medication except contraceptives * drug taken within 4 times the half-life for the specific drug except contraceptives * pregnant or lactating women * exposure to radiation within the last year * headache within the last 24 hours before start of trial * hypertension * hypotension * respiratory or cardiac disease * primary relatives with current or previous migraine
pinot follow-up study in end-stage kidney disease

Conditions: Chronic Kidney Disease

Summary: the primary aims of the patient information about options for treatment (pinot) follow-up study are to determine the proportions of patients, identified in the 2009 pinot cohort that: (i)made the transition to home dialysis, after an initial start on center-based dialysis. (ii)commenced dialysis, or a time-limited trial of dialysis within 3 years, after confirmed plans for conservative care. the hypotheses to be tested in the pinot follow-up study are: 1. 50% of stage 5 chronic kidney disease patients who plan for home dialysis do not commence home dialysis within 3 years, and instead remain on centre-based haemodialysis; and, 2. less than 15% of stage 5 chronic kidney disease patients who plan for conservative care commence dialysis within 3 years.

the secondary aims of the follow-up study include: (i) to assess the primary reasons patients did not transition to home dialysis, in the planned home dialysis group. (ii)to compare 3 and 5 year survival rates among patients who commenced conservative care and patients who commenced renal replacement therapy. (iii) to assess the types of dialysis utilisation over a 5 year time period among the total cohort of patients. (iv)to determine how renal palliative care services were engaged for conservative care patients, and document the patient's place of death (i.e. hospital, hospice, home with community palliative care).

Eligibility criteria:
inclusion criteria: * adults and children with end stage kidney disease (egfr \<15 ml/min) who commenced renal replacement therapy or conservative care in australia between july and september 2009 exclusion criteria: * patients returning to dialysis after a failed transplant, * patients with acute renal failure

Keywords: chronic kidney disease dialysis pre dialysis education transplantation conservative care
the prognostic value of anion gap in predicting major adverse cardiovascular events among patients with st-segment elevation myocardial infarction

Conditions: ST-segment Elevation Myocardial Infarction (STEMI)

Summary: this study aims to evaluate the prognostic value of the anion gap in predicting major adverse cardiovascular events among patients with st-segment elevation myocardial infarction. researchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as st-segment elevation myocardial infarction and underwent primary percutaneous coronary intervention. the data consist of demographic data, clinical presentation, laboratory, and angiography result were collected from hospital registry by reviewing medical record. then, the data was analyzed by using ibm spss statistics v26.


Eligibility criteria:
inclusion criteria: * adults with 18 - 70 years old with diagnosis of stemi who underwent ppci exclusion criteria: * history of heart failure due to any causes * cardiogenic shock before ppci * any infection at the time of presentation * pregnant woman * other causes of high anion gap levels such as chronic kidney disease, metabolic acidosis, etc

Keywords: anion gap major adverse cardiovascular events st-segment elevation myocardial infarction
evaluation of igm-7354 in adults with relapsed and/or refractory cancer

Conditions: Solid Tumor

Summary: this study is a first-in-human (fih), phase 1, multicenter, open-label study to evaluate the safety, tolerability, and pk of igm-7354 in participants with relapsed and/or refractory tumors. the study design consists of a dose-escalation stage and dose-expansion stage. study participation will consist of a 28-day screening period, a treatment period, and a safety follow-up period 90-days after the last dose.

patients will be enrolled in two stages: a dose-escalation stage and an expansion stage. the escalation stage will investigate single agent igm-7354 safety and tolerability in patients with relapsed and/or refractory solid tumors. the dose expansion serial biopsy cohort will assess the intra-tumoral pd changes related to the activity of igm-7354. igm-7354 will be administered intravenously (iv).

Eligibility criteria:
key inclusion criteria: * age \> 18 years at time of signing icf * ecog performance status of 0 or 1 * histologic or cytologic documentation of incurable, locally advanced or metastatic solid tumors for which standard therapies are not available, are no longer effective, are not tolerated, or have been declined by the participant * participants with either measurable or evaluable disease * adequate organ function * at least 2 weeks prior to day 1 or 5 half-lives, whichever is shorter, must have elapsed from the use of anti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy * participants must be willing to have pre-treatment and on-treatment tumor biopsies for biomarker evaluation key exclusion criteria: * inability to comply with study and follow-up procedures * prior il-15, il-2, synthetic il-2, or il-2v based therapy * history of severe allergic or anaphylactic reactions to monoclonal antibody therapy * palliative radiation to bone metastases within 2 weeks prior to day 1 * major surgical procedure within 4 weeks prior to day 1 * untreated or active central nervous system (cns) metastases. patients with a history of treated cns metastases are eligible. * active autoimmune disease that has required systemic treatment in the past 2 years. * diagnosis of immunodeficiency * current grade \>1 toxicity from prior therapy. participants with current grade 2 chronic toxicities that are well-controlled by medications may be enrolled after discussion with medical monitor

Keywords: relapsed and/or refractory metastatic cancer advanced tumors incurable
use of behavioral economics in repeat sars-cov-2 (covid-19) antibody testing in disadvantaged communities

Conditions: SARS-CoV-2

Summary: repeat testing for sars-cov-2 antibodies in disadvantaged communities will help identify active and recovered infections over time, and as more is understood about antibody protection, it may help identify persons who have immunity. many questions about social barriers and behavioral facilitators remain unanswered. this project aims to evaluate the effectiveness of risk-based messaging and incentives that promote repeated testing for sars-cov-2 antibodies, as well as to understand social and behavioral determinants of covid-19 testing and variations within sub-groups of this population.

the rapid spread of the sars-cov-2 virus has greatly impacted underserved populations. this project aims to understand social and behavioral determinants of covid-19 testing and variations within sub-groups of this population. in partnership with the largest federally qualified health center in the united states, investigators will collect survey data and conduct a randomized experiment on 2,160 individuals (540 families) to evaluate the effectiveness of risk-based messaging and incentives that promote repeated testing for sars-cov-2 antibodies. in a 2 x 2 (messaging x incentive) factorial experiment, participants complete a comprehensive set of social and behavioral surveys to identify determinants of commitment to testing. participants are then randomized to receive customized messaging promoting repeated testing. messaging will focus upon either (1a) household risk or (1b) personal risk of covid-19. participants are also randomly assigned to an incentive condition that either (2a) insures against losing baseline rewards for initial testing, or (2b) entry into a lottery with a small chance to win $150 if both tests are completed. both the loss protection and lottery conditions carry the same incentive costs. previous work in similar populations demonstrates that adherence to planned health behaviors is higher with insurance-based incentives than cash payments of equal value. this experiment compares insurance-based incentives to lottery incentives that have been shown to be effective in multiple contexts. finally, the investigators evaluate if social and behavioral determinants of health result in heterogeneous treatment effects that can inform customization of incentive offerings in future programs devoted to increasing uptake of testing or vaccinations among underserved populations.

Eligibility criteria:
inclusion criteria: * adults and children 5 years of age and older exclusion criteria: * children under 5 years of age

Keywords: antibodies
treatment of upper trapezius muscle myofascial pain syndrome

Conditions: Myofascial Pain Syndrome

Summary: the aim of this study is to compare the effects of superficial and deep dry needling techniques, guided by ultrasound, on pain, disability, functional impairment, and quality of life in patients diagnosed with myofascial pain syndrome of the upper trapezius muscle.

myofascial pain syndrome (mas) is a common condition encountered in the daily practice of musculoskeletal medicine. dry needling is a commonly used technique by clinicians in the treatment of myofascial trigger points. dry needling can be classified into two main categories based on the depth of needle insertion: superficial and deep dry needling. dry needling can be performed using either manual palpation techniques or ultrasonographic imaging. ultrasound allows for more precise needle placement. it must be recognized that the depth of needling (superficial insertion vs. deep insertion) varies for every structure and that without ultrasound guidance, differentiation between needling into the superficial fascia and beyond the deep fascia maybe difficult. in clinical settings, using ultrasound can help visualize the different layers and guide the needle to the appropriate depth. the aim of this study is to compare the effectiveness of deep fascia and intramuscular trigger point dry needling techniques, guided by ultrasound, on pain, disability, functional impairment, and quality of life in patients diagnosed with myofascial pain syndrome of the upper trapezius muscle.

Eligibility criteria:
inclusion criteria: 1. diagnosis of mps in the upper trapezius muscle in accordance with criteria defined by travell and simons 2. ages between 20 and 50 years 3. no treatment, including injections, dry needling, and physical methods, applied to the cervical region in the last three months exclusion criteria: 1. bleeding tendency 2. history of neck and shoulder trauma 3. other conditions affecting neck and shoulder pain: including malignancy, infection, rheumatic diseases, degenerative joint disease, fibromyalgia, cervical radiculopathy, neuropathy, myelopathy, myopathy, adhesive capsulitis, etc. 4. cases where evaluation could not be completed for any reason 5. patients who refuse to complete the evaluations
the effect of propofol infusion on total antioxidant status during tourniquet-induced ischemia-reperfusion injury

Conditions: Total Knee Arthroplasty; Tourniquet-Induced Ischemia-Reperfusion Injury

Summary: the release of tourniquet produces reactive oxygen species which can cause injury. propofol is chemically similar to phenol-based free radical scavengers. plasma total antioxidant capacity is a well-established marker of the overall protective effect of antioxidants in body fluids.the aim of the study is to investigate the effects of propofol on ischemia-reperfusion injury in total knee arthroplasty (tka).


Eligibility criteria:
inclusion criteria: * asa i-ii physical status * unilateral total knee arthroplasty * age 18 years to 80 years exclusion criteria: * severe central nervous system disorders * severe cardiopulmonary,renal,metabolic, or hepatic disease, * blood volume deficits, * coagulopathy, * allergy to local anesthetics, * peripheral neuropathies, * body mass index \> 35, * history of antioxidant drug use

Keywords: propofol antioxidant capacity total knee arthroplasty propofol,antioxidant